Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Mini Review

Published on 06 Feb 2025

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities

in Cancer Molecular Targets and Therapeutics

Wen-yu Cai
Xin-xian Cai
Yi-ran Fei
Rui Ye
Ding-ming Song
Dan Hu
Wan-wan Zhang
Ming-fei Xia
Xiao-xiao Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1534055

1,346 views
1 citation

Original Research

Published on 06 Feb 2025

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study

in Cancer Molecular Targets and Therapeutics

Toshiaki Tsurui
Kazuyuki Hamada
Emiko Mura
Risako Suzuki
Nana Iriguchi
Tomoyuki Ishiguro
Yuya Hirasawa
Ryotaro Ohkuma
Masahiro Shimokawa
Hirotsugu Ariizumi

Frontiers in Oncology

doi 10.3389/fonc.2025.1499650

785 views

Original Research

Published on 06 Feb 2025

A pan-cancer analysis of homeobox family: expression characteristics and latent significance in prognosis and immune microenvironment

in Cancer Molecular Targets and Therapeutics

Yuanhui Wang
Jie Gao
Ziyi Ren
Ziyi Shen
Wei Gu
Qinyi Miao
Xiaomeng Hu
Yan Wu
Wei Liu
Jia Jia

Frontiers in Oncology

doi 10.3389/fonc.2025.1521652

874 views

Systematic Review

Published on 04 Feb 2025

Exploring the role of artificial intelligence in chemotherapy development, cancer diagnosis, and treatment: present achievements and future outlook

in Cancer Molecular Targets and Therapeutics

Bassam Abdul Rasool Hassan
Ali Haider Mohammed
Souheil Hallit
Diana Malaeb
Hassan Hosseini

Frontiers in Oncology

doi 10.3389/fonc.2025.1475893

1,902 views
1 citation

Review

Published on 03 Feb 2025

MicroRNA155 in non-small cell lung cancer: a potential therapeutic target

in Cancer Molecular Targets and Therapeutics

Xiangju Wei
Xianmin Xiong
Ze Chen
Bi Chen
Cantang Zhang
Wenhui Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1517995

936 views

Correction

Published on 31 Jan 2025

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

in Cancer Molecular Targets and Therapeutics

Toshio Shimizu
John Powderly
Albiruni Abdul Razak
Patricia LoRusso
Kathy D. Miller
Steven Kao
Sarah Kongpachith
Catherine Tribouley
Michelle Graham
Brian Stoll

Frontiers in Oncology

doi 10.3389/fonc.2024.1544394

683 views

Review

Published on 30 Jan 2025

Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment

in Cancer Molecular Targets and Therapeutics

Yizheng Zhang
Shiqi Yi
Mingyuan Luan

Frontiers in Oncology

doi 10.3389/fonc.2025.1519119

1,532 views

Technology and Code

Published on 29 Jan 2025

VIBE: an R-package for VIsualization of Bulk RNA Expression data for therapeutic targeting and disease stratification

in Cancer Molecular Targets and Therapeutics

Indu Khatri
Saskia D. van Asten
Leandro F. Moreno
Brandon W. Higgs
Christiaan Klijn
Francis Blokzijl
Iris C. R. M. Kolder

Frontiers in Oncology

doi 10.3389/fonc.2024.1441133

1,136 views

Original Research

Published on 29 Jan 2025

Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway

in Cancer Molecular Targets and Therapeutics

Xing Luo
Yi Duan
Jinwei He
CongGai Huang
Jun Liu
Yifan Liu
Mengdei Xu
Qiong Dai
Zhihui Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1429018

703 views

Review

Published on 23 Jan 2025

Ferroptosis in thyroid cancer: mechanisms, current status, and treatment

in Cancer Molecular Targets and Therapeutics

Wenzhi Tian
Xi Su
Chenchen Hu
Dong Chen
Peng Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1495617

1,492 views

Original Research

Published on 22 Jan 2025

Apoptosis antagonizing transcription factor expression and its validation as a potential diagnostic and prognostic biomarker in oral squamous cell carcinoma

in Cancer Molecular Targets and Therapeutics

Ainiwaerjiang Abudourousuli
Zumulaiti Aierken
Hasiyati Mamuti
Tuxunayi Yimamu
Chengli Da

Frontiers in Oncology

doi 10.3389/fonc.2025.1542730

839 views

Review

Published on 22 Jan 2025

Natural killer cell engagers for cancer immunotherapy

in Cancer Molecular Targets and Therapeutics

Shahryar Khoshtinat Nikkhoi
Geng Li
Arash Hatefi

Frontiers in Oncology

doi 10.3389/fonc.2024.1483884

2,809 views

Original Research

Published on 16 Jan 2025

Implication of fibroblast growth factor 7 in ovarian cancer metastases and patient survival

in Cancer Molecular Targets and Therapeutics

Laura F. Mortan
Brooke A. Meelheim
Justin Garland
Jacqueline A. Bohn
Zitha Redempta Isingizwe
Doris M. Benbrook

Frontiers in Oncology

doi 10.3389/fonc.2024.1524606

981 views

Original Research

Published on 16 Jan 2025

Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67

in Cancer Molecular Targets and Therapeutics

Rende Peng
Yaoyu Zhang
Mingzhu Jia
Xinping Yi
Xiaoyao Yi
Shadan Li
Jiangchuan Pi
Wenjun Meng

Frontiers in Oncology

doi 10.3389/fonc.2024.1522009

1,377 views

Case Report

Published on 15 Jan 2025

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

in Cancer Molecular Targets and Therapeutics

Raffaella Pagliaro
Paola Maria Medusa
Fabiana Vitiello
Luigi Aronne
Susan F. M. Campbell
Fabio Perrotta
Andrea Bianco

Frontiers in Oncology

doi 10.3389/fonc.2024.1500449

1,261 views

Systematic Review

Published on 15 Jan 2025

First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis

in Cancer Molecular Targets and Therapeutics

Mengyao Zhang
Lan Sun

Frontiers in Oncology

doi 10.3389/fonc.2024.1498518

1,897 views